Zeposia — Total Revenues
Bristol-Myers Squibb Zeposia — Total Revenues increased by 7.3% to $161.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 9.5%, from $147.00M to $161.00M. Over 3 years (FY 2021 to FY 2024), Zeposia — Total Revenues shows an upward trend with a 61.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market adoption and growth in the immunology therapeutic area, while a decrease may signal increased competition or loss of market share.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Zeposia, a sphingosine-1-phosp...
Peer comparison
Comparable to revenue metrics for specific specialty pharmaceutical products or key growth drivers in the immunology portfolios of major biopharmaceutical peers.
bmy_segment_zeposia_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $28.00M | $40.00M | $48.00M | $36.00M | $66.00M | $69.00M | $79.00M | $78.00M | $100.00M | $123.00M | $133.00M | $110.00M | $151.00M | $147.00M | $158.00M | $107.00M | $150.00M | $161.00M |
| QoQ Change | — | +42.9% | +20.0% | -25.0% | +83.3% | +4.5% | +14.5% | -1.3% | +28.2% | +23.0% | +8.1% | -17.3% | +37.3% | -2.6% | +7.5% | -32.3% | +40.2% | +7.3% |
| YoY Change | — | — | — | — | +135.7% | +72.5% | +64.6% | +116.7% | +51.5% | +78.3% | +68.4% | +41.0% | +51.0% | +19.5% | +18.8% | -2.7% | -0.7% | +9.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's zeposia — total revenues?
- Bristol-Myers Squibb (BMY) reported zeposia — total revenues of $161.00M in Q3 2025.
- How has Bristol-Myers Squibb's zeposia — total revenues changed year-over-year?
- Bristol-Myers Squibb's zeposia — total revenues increased by 9.5% year-over-year, from $147.00M to $161.00M.
- What is the long-term trend for Bristol-Myers Squibb's zeposia — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's zeposia — total revenues has grown at a 61.6% compound annual growth rate (CAGR), from $134.00M to $566.00M.
- What does zeposia — total revenues mean?
- The total revenue generated from sales of the drug Zeposia.